Concepts (157)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunotherapy, Adoptive | 12 | 2025 | 899 | 1.980 |
Why?
|
| T-Lymphocytes | 11 | 2025 | 1758 | 1.740 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 10 | 2023 | 1190 | 1.480 |
Why?
|
| Receptors, Antigen, T-Cell | 8 | 2023 | 500 | 0.970 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2025 | 24 | 0.960 |
Why?
|
| Osteopontin | 1 | 2025 | 51 | 0.950 |
Why?
|
| Epstein-Barr Virus Infections | 3 | 2023 | 293 | 0.940 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2025 | 142 | 0.900 |
Why?
|
| Neuroblastoma | 4 | 2025 | 548 | 0.870 |
Why?
|
| Gangliosides | 1 | 2024 | 73 | 0.830 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2023 | 165 | 0.710 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2024 | 215 | 0.710 |
Why?
|
| Virus Diseases | 1 | 2023 | 291 | 0.650 |
Why?
|
| Biological Specimen Banks | 1 | 2019 | 55 | 0.610 |
Why?
|
| Adoptive Transfer | 1 | 2019 | 241 | 0.570 |
Why?
|
| Cytomegalovirus | 1 | 2019 | 263 | 0.570 |
Why?
|
| Transplant Recipients | 1 | 2019 | 225 | 0.550 |
Why?
|
| DNA Virus Infections | 1 | 2017 | 22 | 0.550 |
Why?
|
| DNA Viruses | 1 | 2017 | 32 | 0.540 |
Why?
|
| CD28 Antigens | 1 | 2017 | 82 | 0.530 |
Why?
|
| CD3 Complex | 1 | 2017 | 92 | 0.520 |
Why?
|
| Herpesvirus 4, Human | 5 | 2023 | 675 | 0.490 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2017 | 210 | 0.490 |
Why?
|
| Tissue Donors | 1 | 2019 | 503 | 0.490 |
Why?
|
| Transplantation Conditioning | 5 | 2023 | 300 | 0.470 |
Why?
|
| Leukemia, Myeloid, Acute | 4 | 2025 | 570 | 0.440 |
Why?
|
| Neoplasms | 3 | 2025 | 2947 | 0.410 |
Why?
|
| Graft vs Host Disease | 3 | 2023 | 621 | 0.400 |
Why?
|
| Transplantation, Homologous | 5 | 2023 | 648 | 0.360 |
Why?
|
| Lymphoma | 2 | 2024 | 331 | 0.340 |
Why?
|
| Neoplasms, Second Primary | 1 | 2012 | 149 | 0.340 |
Why?
|
| Hematologic Neoplasms | 2 | 2025 | 294 | 0.330 |
Why?
|
| Leukemia | 2 | 2024 | 373 | 0.320 |
Why?
|
| Interleukin-7 | 3 | 2023 | 50 | 0.320 |
Why?
|
| Hodgkin Disease | 1 | 2012 | 305 | 0.310 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2025 | 1002 | 0.300 |
Why?
|
| Tumor Microenvironment | 4 | 2025 | 694 | 0.260 |
Why?
|
| Child | 15 | 2025 | 25777 | 0.250 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2019 | 816 | 0.240 |
Why?
|
| Alemtuzumab | 3 | 2023 | 88 | 0.230 |
Why?
|
| Child, Preschool | 11 | 2025 | 14831 | 0.230 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 1347 | 0.230 |
Why?
|
| Cytotoxicity, Immunologic | 4 | 2019 | 267 | 0.220 |
Why?
|
| Cell Line, Tumor | 5 | 2025 | 3700 | 0.220 |
Why?
|
| Humans | 28 | 2025 | 132278 | 0.220 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2024 | 21 | 0.220 |
Why?
|
| beta-Thalassemia | 1 | 2023 | 30 | 0.210 |
Why?
|
| Neoplasm Grading | 1 | 2024 | 302 | 0.200 |
Why?
|
| Adolescent | 13 | 2025 | 20510 | 0.200 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2023 | 47 | 0.200 |
Why?
|
| Mice | 7 | 2025 | 18622 | 0.180 |
Why?
|
| CD27 Ligand | 1 | 2021 | 5 | 0.180 |
Why?
|
| Single-Chain Antibodies | 1 | 2021 | 45 | 0.180 |
Why?
|
| Young Adult | 6 | 2024 | 9936 | 0.170 |
Why?
|
| Adult | 12 | 2024 | 31585 | 0.170 |
Why?
|
| Clinical Trials as Topic | 1 | 2025 | 1152 | 0.170 |
Why?
|
| Infant | 6 | 2025 | 13177 | 0.170 |
Why?
|
| Female | 13 | 2025 | 70773 | 0.160 |
Why?
|
| Tissue Banks | 1 | 2019 | 30 | 0.160 |
Why?
|
| Glioma | 1 | 2024 | 534 | 0.150 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2019 | 51 | 0.140 |
Why?
|
| Antigens, CD19 | 1 | 2019 | 182 | 0.140 |
Why?
|
| HLA Antigens | 1 | 2019 | 220 | 0.140 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2019 | 169 | 0.140 |
Why?
|
| Wiskott-Aldrich Syndrome | 1 | 2017 | 23 | 0.140 |
Why?
|
| Lymphoma, B-Cell | 1 | 2019 | 148 | 0.140 |
Why?
|
| Follow-Up Studies | 5 | 2025 | 5399 | 0.140 |
Why?
|
| Animals | 7 | 2025 | 35136 | 0.140 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2019 | 771 | 0.140 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2018 | 70 | 0.140 |
Why?
|
| Anemia, Sickle Cell | 1 | 2021 | 344 | 0.130 |
Why?
|
| Cytomegalovirus Infections | 1 | 2019 | 225 | 0.130 |
Why?
|
| Adenoviruses, Human | 1 | 2017 | 98 | 0.130 |
Why?
|
| Lectins, C-Type | 1 | 2017 | 73 | 0.130 |
Why?
|
| Leukocyte Common Antigens | 1 | 2017 | 91 | 0.130 |
Why?
|
| Antiviral Agents | 1 | 2023 | 823 | 0.130 |
Why?
|
| Herpesvirus 6, Human | 1 | 2017 | 55 | 0.130 |
Why?
|
| BK Virus | 1 | 2017 | 60 | 0.130 |
Why?
|
| Neoplasm Proteins | 1 | 2021 | 703 | 0.130 |
Why?
|
| Immunotherapy | 1 | 2022 | 746 | 0.130 |
Why?
|
| Interleukin-15 | 1 | 2017 | 96 | 0.130 |
Why?
|
| Interleukin-2 | 1 | 2017 | 241 | 0.130 |
Why?
|
| Immunophenotyping | 1 | 2017 | 344 | 0.130 |
Why?
|
| Killer Cells, Natural | 1 | 2019 | 353 | 0.120 |
Why?
|
| Male | 11 | 2025 | 64993 | 0.120 |
Why?
|
| Autoimmune Diseases | 1 | 2018 | 273 | 0.120 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2017 | 234 | 0.110 |
Why?
|
| Lymphocyte Activation | 1 | 2017 | 686 | 0.110 |
Why?
|
| Flow Cytometry | 1 | 2017 | 806 | 0.110 |
Why?
|
| Cerebroside-Sulfatase | 1 | 1994 | 9 | 0.110 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2017 | 519 | 0.110 |
Why?
|
| Glioblastoma | 1 | 2017 | 374 | 0.100 |
Why?
|
| Leukocytes | 1 | 1994 | 210 | 0.100 |
Why?
|
| Retrospective Studies | 8 | 2025 | 17344 | 0.100 |
Why?
|
| Cardiovascular Diseases | 1 | 2025 | 2060 | 0.090 |
Why?
|
| Radiotherapy Dosage | 1 | 2012 | 237 | 0.090 |
Why?
|
| Treatment Outcome | 3 | 2019 | 13002 | 0.090 |
Why?
|
| Age of Onset | 1 | 2012 | 625 | 0.080 |
Why?
|
| Unrelated Donors | 2 | 2021 | 70 | 0.080 |
Why?
|
| Cell Differentiation | 1 | 2017 | 1990 | 0.080 |
Why?
|
| Aged | 6 | 2024 | 21347 | 0.070 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2022 | 356 | 0.070 |
Why?
|
| Recurrence | 2 | 2022 | 1458 | 0.070 |
Why?
|
| Middle Aged | 6 | 2024 | 28847 | 0.060 |
Why?
|
| Cytokines | 2 | 2023 | 1368 | 0.060 |
Why?
|
| Lymphocyte Depletion | 1 | 2024 | 125 | 0.050 |
Why?
|
| Busulfan | 1 | 2023 | 43 | 0.050 |
Why?
|
| Neutropenia | 1 | 2024 | 205 | 0.050 |
Why?
|
| Consensus | 1 | 2025 | 656 | 0.050 |
Why?
|
| Thrombocytopenia | 1 | 2024 | 233 | 0.050 |
Why?
|
| Risk Factors | 2 | 2017 | 10894 | 0.050 |
Why?
|
| THP-1 Cells | 1 | 2021 | 24 | 0.050 |
Why?
|
| Research Design | 1 | 2025 | 749 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2023 | 425 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2017 | 2515 | 0.040 |
Why?
|
| Retroviridae | 1 | 2019 | 195 | 0.040 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2019 | 17 | 0.040 |
Why?
|
| K562 Cells | 1 | 2019 | 98 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2021 | 796 | 0.040 |
Why?
|
| Chemokines | 1 | 2019 | 131 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 436 | 0.040 |
Why?
|
| Chimerism | 1 | 2018 | 29 | 0.040 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2018 | 31 | 0.040 |
Why?
|
| Pancytopenia | 1 | 2018 | 41 | 0.040 |
Why?
|
| Multiple Sclerosis | 1 | 2001 | 382 | 0.030 |
Why?
|
| Receptors, Cytokine | 1 | 2017 | 67 | 0.030 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2017 | 56 | 0.030 |
Why?
|
| Ligands | 1 | 2019 | 504 | 0.030 |
Why?
|
| Allografts | 1 | 2017 | 196 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2018 | 273 | 0.030 |
Why?
|
| Adenoviridae | 1 | 2019 | 596 | 0.030 |
Why?
|
| Vaccines, Attenuated | 1 | 2017 | 176 | 0.030 |
Why?
|
| Myeloid Cells | 1 | 2017 | 119 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 243 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2019 | 933 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 956 | 0.030 |
Why?
|
| Prognosis | 1 | 2025 | 5006 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2017 | 403 | 0.030 |
Why?
|
| Dendritic Cells | 1 | 2017 | 448 | 0.030 |
Why?
|
| Texas | 1 | 2021 | 3629 | 0.020 |
Why?
|
| Gene Expression | 1 | 2017 | 1569 | 0.020 |
Why?
|
| Survival Rate | 1 | 2017 | 2186 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2023 | 6534 | 0.020 |
Why?
|
| Lysosomes | 1 | 1994 | 262 | 0.020 |
Why?
|
| Vaccination | 1 | 2017 | 1017 | 0.020 |
Why?
|
| Incidence | 1 | 2018 | 3358 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 2072 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 4681 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 7102 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 1994 | 1686 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2017 | 4737 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2018 | 8558 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 2001 | 249 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2001 | 440 | 0.010 |
Why?
|
| Monocytes | 1 | 2001 | 345 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2001 | 542 | 0.010 |
Why?
|
| Disease Progression | 1 | 2001 | 2228 | 0.010 |
Why?
|